Target Name: RNF183
NCBI ID: G138065
Other Name(s): OTTHUMP00000215895 | probable E3 ubiquitin-protein ligase RNF183 | E3 ubiquitin-protein ligase RNF183 | Ring finger protein 183, transcript variant 1 | ring finger protein 183 | RNF183 variant 1 | OTTHUMP00000215896 | RN183_HUMAN | FLJ31197 | OTTHUMP00000215897 | MGC4734

RNA-Fucose: A Promising Drug Target and Biomarker

RNA-Fucose (RNA-F) is a sugar derived from the blood plasma of red blood cells. It is a crucial component of the blood and plays a vital role in maintaining the health of the body. However, RNA-Fucose has also been found to have potential as a drug target or biomarker.

The RNA-Fucose molecule has been shown to play a key role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to a growing interest in using RNA-Fucose as a drug or biomarker.

One of the reasons for the interest in RNA-Fucose as a drug target is its unique structure. RNA-Fucose has a unique sugar-protein structure, which makes it difficult for the body to break it down and remove it from the body. This unique structure has allowed researchers to study the molecule's interactions with the immune system and has led to the development of new treatments for diseases.

RNA-Fucose has also been shown to be a potential biomarker for disease. Its levels can be easily measured and have been used to diagnose and monitor a variety of diseases, including cancer, diabetes, and neurodegenerative disorders. This has led to the development of new diagnostic tests for these diseases and has improved the accuracy of disease diagnosis.

In addition to its potential as a drug target and biomarker, RNA-Fucose has also been shown to have potential as a therapeutic agent. Studies have shown that RNA-Fucose can be used to treat a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune disorders. The unique structure of RNA-Fucose has allowed it to be used in a variety of formats, including injections, oral tablets, and intravenous infusions.

Overall, RNA-Fucose is a promising drug target and biomarker that has the potential to improve the health and treatment of a variety of diseases. Further research is needed to fully understand its potential and to develop new treatments for the diseases that are currently treated with limited success.

Protein Name: Ring Finger Protein 183

Functions: Acts as a E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins (PubMed:29507230). Triggers apoptosis in response to prolonged ER stress by mediating the polyubiquitination and subsequent proteasomal degradation of BCL2L1 (PubMed:29507230). May collaborate with FATE1 to restrain BIK protein levels thus regulating apoptotic signaling (PubMed:26567849)

More Common Targets

RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P | RNU105B | RNU11 | RNU12 | RNU2-1 | RNU2-17P | RNU2-2P | RNU2-4P | RNU2-54P | RNU2-5P | RNU2-6P | RNU4-1 | RNU4-14P | RNU4-2 | RNU4-30P | RNU4-33P | RNU4-38P | RNU4-39P | RNU4-46P | RNU4-53P